Intestinal permeability in the pathogenesis of NSAID-induced enteropathy

  title={Intestinal permeability in the pathogenesis of NSAID-induced enteropathy},
  author={Ingvar T. Bjarnason and Ken Takeuchi},
  journal={Journal of Gastroenterology},
BackgroundThe pathogenesis of nonsteroidal antiinflammatory drug (NSAID)-induced small bowel disease suggests that increased intestinal permeability is the central mechanism that translates biochemical damage to tissue damage. The purpose of this review is to summarize studies on the effect of NSAIDs to increase intestinal permeability in humans and methods for limiting this effect.MethodsA Medline search was made for papers that described measurements of increased intestinal permeability in… 

Mechanisms of Damage Involved in Small Intestinal Tract Caused by Nonsteroidal Anti-Inflammatory Drugs

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used type of drugs, as they are very effective as antiinflammatory, anti-pyretic and analgesic. Their use has increased

NSAID enteropathy: could probiotics prevent it?

The main therapeutic strategies for NSAID enteropathy are reviewed, in particular analyzing the available studies relating to the eventual protective role of probiotics, and it is found that results are not all concordant.

NSAID-Induced Enteropathy: Are the Currently Available Selective COX-2 Inhibitors All the Same?

It is suggested that nonselective NSAIDs and etoricoxib can induce enteropathy through a topic action, whereas celecoxib lacks relevant detrimental actions.

Pathophysiology of NSAID-Associated Intestinal Lesions in the Rat: Luminal Bacteria and Mucosal Inflammation as Targets for Prevention

Rifaximin prevents diclofenac-induced enteropathy through both anti-bacterial and anti-inflammatory activities.

Proton pump inhibitors exacerbate NSAID-induced small intestinal injury by inducing dysbiosis.

PPIs exacerbate NSAID-induced intestinal damage at least in part because of significant shifts in enteric microbial populations, and prevention or reversal of this dysbiosis may be a viable option for reducing the incidence and severity of NSAID enteropathy.

Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease

This alteration of gut microbiota may contribute to nonalcoholic fatty liver disease and its related disorders in two ways: firstly causing a malfunction of the tight junctions that play a critical role in the increase of intestinal permeability, and then leading to the development of insulin resistance, body weight gain, lipogenesis, fibrogenesis and hepatic oxidative stress.

Small Bowel Tissue Concentration of Rebamipide: Study of Two Dosages in Healthy Subjects

The COR level in the jejunum was sufficient to protect for NSAID-induced gastrointestinal complications, and the mean COR in the stomach was less than 100 µM at 1 h in the 100 mg group; however it was higher than100 µM in the 200 mg group.



Recent insight into the mechanism of gastrointestinal tract ulceration.

There is a correlation between biliary excretion of NSAIDs or ester conjugates of these drugs and ileal perforations in rats, and it may be safely assumed that the enterohepatic circulation of some NSAIDs, particularly indomethacin and piroxicam, may contribute to the reported incidence of ILEal and jejunal damage caused by these drugs.

Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man.

It is suggested that NSAIDs increase intestinal permeability during absorption or after biliary excretion and that the systemic effect is of minor importance.

COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice.

COX-1 deficiency or inhibition and short-term COX-2 inhibition are compatible with normal small intestinal integrity and associated with significant intestinal pathology despite normal intestinal PGE(2) levels, suggesting a role for COx-2 in the maintenance of small intestine integrity in the mouse.

NSAID-induced intestinal damage: are luminal bacteria the therapeutic target?

suggests that inhibition of both COX-1 and COX-2 is necessary to cause significant GI damage. The importance of PG deficiency in the pathogenesis of NSAIDinduced intestinal damage is confirmed by the

The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis.

Non-steroidal anti-inflammatory drugs (NSAIDs) are amongst the most successful group of drugs ever marketed, which demonstrates their overall efficacy. They are not, however, without side effects

Intestinal tolerability of nitroxybutyl-flurbiprofen in rats.

Nitroxybutyl-flurbiprofen is associated with significantly less macroscopic damage in the small intestine than flurbip rofen but was associated with mitochondrial damage in vivo and caused similar increases in permeability of the small intestinal, suggesting that its beneficial effect is on the later pathogenic stages of the damage.

Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine.

The studies show that non-steroidal anti-inflammatory drugs disrupt the intestinal barrier function in man and suggest that the morphological correlates of the damage may reside at the level of the intercellular junctions.

Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs

This study provides evidence that the newly developed NSAIDs reduce gastric mucosal permeability significantly and suggests that celecoxib seems to exhibit the most desirable gastrointestinal side effect profile.